10 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $564M | $37M | 0.0% | 7.9% | -$24M | — | $94M |
| 2024 | $482M | $900000 | 76.0% | -0.3% | $4M | — | $136M |
| 2023 | $433M | $5M | 75.4% | 2.9% | $7M | $67M | $104M |
| 2022 | $451M | $16M | 76.7% | 4.9% | -$9M | $71M | $102M |
| 2021 | $467M | $94M | 75.6% | 15.5% | $31M | $74M | $114M |
| 2020 | $338M | $17M | 74.2% | 7.9% | -$12M | $70M | $84M |
| 2019 | $261M | -$39M | 70.9% | -11.4% | -$40M | $50M | — |
| 2018 | $193M | -$65M | 64.4% | -26.7% | -$62M | — | — |
| 2017 | $199M | -$8M | 69.2% | -2.8% | -$6M | $52M | — |
| 2016 | $139M | -$17M | 65.3% | -6.3% | -$6M | — | — |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $37M | -$53M | 0.0% | -185.1% | $18M | — | $91M |
| Dec '25 | $226M | $44M | 0.0% | 28.1% | $35M | — | $94M |
| Sep '25 | $151M | $22M | 0.0% | 13.7% | $844000 | — | $64M |
| Jun '25 | $101M | -$9M | 0.0% | -12.5% | -$37M | — | $73M |
| Mar '25 | $87M | -$19M | 72.6% | -30.9% | -$24M | — | $110M |
| Dec '24 | $127M | $8M | 75.5% | 8.1% | $8M | — | $136M |
| Sep '24 | $115M | $12M | 76.7% | 5.4% | $6M | $62M | $94M |
| Jun '24 | $130M | -$17M | 77.6% | -10.7% | $3M | $64M | $90M |
| Mar '24 | $110M | -$2M | 73.9% | -3.5% | -$12M | $65M | $89M |
| Dec '23 | $100M | -$568000 | 72.1% | -1.3% | $7M | $67M | $104M |
| Sep '23 | $109M | $3M | 76.2% | 7.4% | $11M | $68M | $98M |
| Jun '23 | $117M | $5M | 77.6% | 8.3% | $1M | $69M | $89M |
| Mar '23 | $108M | -$3M | 75.3% | -3.7% | -$13M | $70M | $89M |
| Dec '22 | $116M | $7M | 76.5% | 7.5% | -$3M | $71M | $102M |
| Sep '22 | $117M | $215000 | 77.6% | 1.5% | -$5M | $73M | $107M |
| Jun '22 | $121M | $9M | 78.0% | 9.8% | $4M | $73M | $112M |
| Mar '22 | $97M | -$913000 | 74.2% | -0.1% | -$5M | $74M | $108M |
| Dec '21 | $128M | $51M | 74.5% | 15.4% | $13M | $74M | $114M |
| Sep '21 | $114M | $13M | 77.0% | 14.3% | $11M | $75M | — |
| Jun '21 | $123M | $21M | 75.7% | 19.1% | $13M | $70M | — |
How the market has priced ORGO against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Organogenesis Holdings Inc.'s revenue has grown 10.8% per year, and net income grown 16.5% per year. These are computed facts, not advice.
As of FY2025, Organogenesis Holdings Inc. reported — of total debt against $94M of cash; operating income covered interest expense -19.6×.
In FY2025, gross margin was —, operating margin 7.9%, and net margin 6.6%.
As of Jun '26, Organogenesis Holdings Inc. traded at a price-to-earnings ratio of about 8.4× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.